Trial Profile
A prospective, randomised, double-blinded, placebo-controlled, single ascending dose study investigating the safety and local tolerability of STA363 compared to placebo in 15 patients with chronic discogenic low back pain
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Oct 2020
Price :
$35
*
At a glance
- Drugs Lactic acid (Primary)
- Indications Back pain
- Focus Adverse reactions; First in man
- Sponsors Stayble Therapeutics
- 07 Oct 2020 According to a Stayble Therapeutics media release, data from this trial will be presented at the EuroSpine Annual Meeting.
- 01 Oct 2020 According to a Stayble Therapeutics media release, a scientific article based on pre-clinical studies and this clinical phase 1b study results with STA363 has been published in the highly prestigious scientific journal Spine.
- 01 Oct 2020 Results presented in a Stayble Therapeutics media release.